Erasca, Inc. develops precision oncology therapies for cancers driven by the RAS/MAPK pathway. News on ERAS commonly centers on its RAS-targeting pipeline, including ERAS-0015, an investigational oral pan-RAS molecular glue evaluated in RAS-mutant solid tumors, and ERAS-4001, an oral pan-KRAS inhibitor for KRAS-mutant solid tumors.
Company updates frequently cover Phase 1 clinical data, dose-escalation results, trial collaborations and supply agreements, intellectual-property protection, development rights, public offering activity, financial results, and healthcare conference presentations. Recurring cancer settings in company disclosures include non-small cell lung cancer, pancreatic adenocarcinoma, colorectal cancer, and other RAS-mutant solid tumors.
Tango Therapeutics (TNGX) and Erasca (ERAS) opened enrollment in a Phase 1/2 trial combining vopimetostat with ERAS-0015 for pancreatic and lung cancers.
The study enrolls patients with pancreatic ductal adenocarcinoma with an MTAP gene deletion, or non-small cell lung cancer with both an MTAP deletion and a RAS mutation. Tango sponsors the multicenter, open-label trial, in which participants and investigators know the treatment given. It includes dose escalation followed by expansion. The primary dose-escalation objective is to determine the combination's maximum tolerated dose; secondary objectives assess antitumor activity, drug exposure, safety and tolerability.
Vopimetostat inhibits PRMT5, while ERAS-0015 targets RAS signaling. Tango reports durable activity with vopimetostat in ongoing studies across multiple MTAP-deleted tumor types, including pancreatic and lung cancers.
Erasca (ERAS) management will participate in three investor conferences in November 2026, with fireside chats and one-on-one investor meetings at each.
The chats are scheduled for November 10 at 3:30 pm Eastern in Boston, November 11 at 9:20 am Eastern in New York, and November 18 at 12:30 pm Greenwich Mean Time in London. Live audio webcasts and archived replays for 30 days will be available at Erasca.com/events.
Erasca (ERAS) will present updated monotherapy clinical data for ERAS-0015 from the ongoing Phase 1 AURORAS-1 trial and nonclinical combination data for ERAS-0015 plus ERAS-4001 at the 38th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, held November 18-20 in Barcelona, Spain.
The oral presentation will cover preliminary safety, pharmacokinetics, and efficacy results of ERAS-0015 in its first-in-human trial. A poster will detail nonclinical data showing that combining ERAS-0015, a potential best-in-class pan-RAS molecular glue, with ERAS-4001, a potential first- and best-in-class pan-KRAS inhibitor, targets active and inactive KRAS and demonstrates synergy in KRAS G12X-driven models.
Erasca (ERAS) will present at the Morgan Stanley 24th Annual Global Healthcare Conference at the New York Marriott Marquis in New York, NY. Management is scheduled for a fireside chat on Tuesday, September 15, 2026, at 1:05 p.m. Eastern Time and will hold one-on-one investor meetings. A live audio webcast and a 30-day archived replay will be accessible at Erasca.com/events.
Erasca (Nasdaq: ERAS) announced that the U.S. Food and Drug Administration granted Fast Track Designation (FTD) to its oral pan-RAS molecular glue ERAS-0015 for treating patients with metastatic pancreatic adenocarcinoma. ERAS-0015 is designed to inhibit RAS signaling and is being evaluated for a potential best-in-class profile.
According to Erasca, FTD, which supports development of therapies for serious conditions with unmet needs, may provide more frequent FDA interactions and potential eligibility for accelerated approval, priority review, and rolling review. The designation follows preliminary Phase 1 AURORAS-1 data in second-line or later KRAS G12X pancreatic ductal adenocarcinoma, where ERAS-0015 monotherapy at the 32 mg once-daily recommended dose for expansion showed a 57% uORR8wk, with all responding patients across doses remaining on treatment at the May 25, 2026 cutoff and a favorable tolerability profile. Erasca plans three potentially registration-enabling trials across pancreatic and lung cancers and expects additional monotherapy and combination data, including with panitumumab, in the first half of 2027.
Erasca (Nasdaq: ERAS) reported second quarter 2026 business updates highlighting ERAS-0015 and ERAS-4001 pipeline progress alongside a significantly strengthened balance sheet. Updated AURORAS-1 Phase 1 data showed a 57% uORR8wk for ERAS-0015 monotherapy in 2L+ KRAS G12X pancreatic ductal adenocarcinoma at the 32 mg QD dose, with ongoing treatment in all responding patients and favorable tolerability, including no dose-limiting toxicities or treatment-related discontinuations.
Erasca is advancing ERAS-0015 toward three potentially registration-enabling trials in pancreatic and lung cancers between 2027 and early 2028 and expects preliminary Phase 1 monotherapy data for ERAS-4001 in H2 2026. Cash, cash equivalents, and marketable securities were $384.3 million at June 30, 2026, and the company raised approximately $632.5 million in gross proceeds from an upsized July 2026 public offering. R&D expenses rose to $35.9 million and G&A expenses to $11.7 million, contributing to a net loss of $44.1 million, or $(0.14) per share, for the quarter.
Erasca (Nasdaq: ERAS) announced that its Board approved inducement equity awards in connection with the appointment of Charles S. Fuchs, M.D., M.P.H., as president of research and development. Under Erasca’s 2026 Employment Inducement Incentive Award Plan, Dr. Fuchs received non-qualified stock options to purchase 1,278,520 shares of common stock.
According to Erasca, the options were granted on August 10, 2026 at an exercise price equal to the closing price of Erasca common stock on the Nasdaq Global Select Market that day. Twenty-five percent of the options will vest on August 10, 2027, with the remainder vesting in 36 equal monthly installments thereafter, consistent with Nasdaq Listing Rule 5635(c)(4) for inducement grants.
Erasca (Nasdaq: ERAS), a clinical-stage precision oncology company focused on RAS/MAPK pathway-driven cancers, appointed Charles S. Fuchs, M.D., M.P.H. as president of research and development, effective immediately.
According to Erasca, Dr. Fuchs brings over three decades of oncology leadership, spanning drug development, scientific innovation, and patient care. His experience includes work that has contributed to multiple approved cancer therapies and deep expertise in gastrointestinal cancers. Erasca said his background will help shape its R&D strategy as it expands development and prepares for potential future commercialization of its RAS-targeting franchise, which aims to shut down RAS-driven cancers and address unmet needs across multiple tumor types.
Erasca (Nasdaq: ERAS) closed its previously announced upsized public offering of 36,142,857 common shares, including 4,714,285 shares from the underwriters’ full over‑allotment option, at $17.50 per share. Gross proceeds to Erasca were approximately $632.5 million before underwriting discounts, commissions, and expenses.
According to Erasca, all shares were issued by the company, and it plans to use the net proceeds, together with existing cash, cash equivalents, and marketable securities, to fund research and development of its oncology product candidates, other development programs, and for working capital and general corporate purposes. The offering was conducted under an effective shelf registration on Form S‑3, with J.P. Morgan, Morgan Stanley, Jefferies, and Evercore ISI serving as joint book‑running managers.
Erasca (Nasdaq: ERAS) priced an upsized public offering of 31,428,572 common shares at $17.50 per share, for expected gross proceeds of about $550 million before fees and expenses. All shares are being sold by Erasca.
The company granted underwriters a 30-day option to buy up to 4,714,285 additional shares at the offering price, less underwriting discounts and commissions. The offering is expected to close on July 15, 2026, subject to customary conditions. According to Erasca, net proceeds plus existing cash will fund R&D, other development programs, and general corporate purposes.